Immunotherapy Advances in Multiple Myeloma

Immunotherapy Advances in Multiple Myeloma

Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. New strategies such as monoclonal antibody therapies. antibody-drug conjugates, immune checkpoint therapy, adoptive cell therapies such as natural killer cells, marrow infiltrating lymphocytes, dendritic cells, CAR T cell therapies and cancer vaccines represent the basis for next generation myeloma therapies. We are talking to Dr. Saad Usmani of Levine Cancer Institute / Carolinas Healthcare System about the latest advances in immunotherapy for multiple myeloma. 


Talk Recorded on April 18, 2017, 6 p.m.   EST 944 7

Hear Talk Audio

  • Anonymous User April 18, 2017, 6:38 p.m.  US/Eastern

    For CPI's - are you seeing any benefit in using PD 1 v.s PDL-1?

  • Anonymous User April 18, 2017, 6:30 p.m.  US/Eastern

    As the duration of use of Daratumamab, are you seeing new or unexpected side effects e.g. extramedullary relapses and symptomatic hypoglobulinemia requiring IVIG.

  • Anonymous User April 18, 2017, 6:30 p.m.  US/Eastern

    I am a candidate for an autologous stem cell transplant. my myeloma is slow developing. I have responded well to cytoxin and decadron regimen. my numbers are great. is the transplant still considered the gold standard for myeloma treatment?

  • Anonymous User April 18, 2017, 1:15 a.m.  US/Eastern

    Have been reading about life threatening neurological toxicities associated with CAR T cell therapy. Could you please tell us a bit more about these.

  • Anonymous User April 18, 2017, 1:07 a.m.  US/Eastern

    It is known that the CAR T cells expand in number within a patients body leading to toxicities. What has been the advances, if any, over the last few years, to tackle this problem?

  • Anonymous User April 18, 2017, 12:38 a.m.  US/Eastern

    Have there been any advances that you can share, towards dealing with the adverse effects related to immunotherapies. Are there any upcoming clinical trials related to that, that we should know about?

  • priya menon April 18, 2017, 12:26 a.m.  US/Eastern

    Most of the multiple myeloma patients become resistant to existing therapies or relapse. How long do you predict, the effects of a particular immunotherapy will last on patients before they start showing resistance.